RxDoctor Payments Data

Edith Ama

Family · Detroit, MINPI 1558835868

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Exact Sciences at 25.4% of the total. 2025 is the largest year on record at $101, 2.1 times the $48 reported in 2022. That places this record below the midpoint for family clinicians in MI, where the typical reported total is $349.

$235in general payments, 2019–2025

Across 11 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$60
  • Hologic Sales And Service, LLC$48
  • E.r. Squibb & Sons, L.L.C.$28
  • Abiomed$24
  • Teva Pharmaceuticals USA, Inc.$19
  • Dynavax Technologies Corporation$19
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$235 in reported general payments places this provider in the 40th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$208
Medicare patients
27
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$75,735
JardianceEmpagliflozin91$60,058
TrulicityDulaglutide27$26,132
OzempicSemaglutide22$20,345
EliquisApixaban19$15,715
Breo ElliptaFluticasone/Vilanterol23$9,161
SymbicortBudesonide/Formoterol Fumarate25$6,984
Famotidine122$6,961
Albuterol Sulfate HfaAlbuterol Sulfate215$6,612
Spiriva HandihalerTiotropium Bromide11$5,669
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$4,341
Atorvastatin Calcium403$2,385
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,343
Ventolin HfaAlbuterol Sulfate19$1,387
Losartan Potassium201$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$18$84,897115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,657 family providers in Michigan.

Other family in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →